giikorea.co.kr
 È¨ | ȸ»ç¼Ò°³ | ¸ÂÃãÇü ½ÃÀåÁ¶»ç | ±¹Á¦ÄÁÆÛ·±½º | ±Û·Î¹ú ÆÄÆ®³Ê | īŻ·Î±× | ¿¬¶ôó | Site Map |

Conference banner
  Page:   1  2   

Reports

Ç×¹ÙÀÌ·¯½º Ä¡·á : ±â¼ú¡¤½ÃÀ塤±â¾÷
Antiviral Therapeutics - technologies, markets and companies
  Pub Time : 2010/03
  Published by : Jain Pharmabiotech
°¢Á¾ Ç×¹ÙÀÌ·¯½º Ä¡·á ±â¼ú, ½ÃÀå µ¿Çâ, ±â¾÷ Á¤º¸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¾Ï ¸é¿ª¿ä¹ý : ¾àÁ¦ ÆÄÀÌÇÁ¶óÀÎ - 2010³â
Immunotherapy in Oncology Drug Pipeline Update 2010
  Pub Time : 2010/01
  Published by : BioSeeker Group AB
¾Ï ¸é¿ª¿ä¹ýÀÇ ¾àÁ¦ °³¹ß ´Ü°è, °³¹ß ÇÁ·ÎÁ§Æ®, Ç¥Àû, ¾àÁ¦ ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¾Ï ´ë»ó »çÀÌÅäÄ«ÀÎ Ä¡·á ¾àÁ¦ ÆÄÀÌÇÁ¶óÀÎ : 2010³â Ãֽе¿Çâ
Cytokine Therapy in Oncology Drug Pipeline Update 2010
  Pub Time : 2010/01
  Published by : BioSeeker Group AB
¾Ï ´ë»ó »çÀÌÅäÄ«ÀÎ Ä¡·á ¾àÁ¦ °³¹ß¿¡ ÃÊÁ¡À» ¸ÂÃß¾î, ±× °³¹ß ÁøÃ´ µ¿Çâ ¹× ´Ù¾çÇÑ Ç¥Àû µî¿¡ ´ëÇØ¼­ ÀüÇØµå¸³´Ï´Ù.

ºÐ¼® Åø : ¾ÏÄ¡·á¿ë Ç×ü
Analytical Tool - Cancer Therapeutic Antibodies
  Pub Time : 2010/01
  Published by : BioSeeker Group AB
¾ÏÄ¡·á¿ë Ç×ü¿¡ °ü·ÃµÈ ÇöÀçÀÇ ¿¬±¸°³¹ß µ¿Çâ, ÇöÀç±îÁöÀÇ ¼º°ú, ÇâÈÄÀÇ ¹æÇ⼺, ÇöÀçÀÇ Ä¡·á Àü·« µî¿¡ ´ëÇØ Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¾ÏÄ¡·á¿ë Ç×ü ÆÄÀÌÇÁ¶óÀÎ : 2010³â Ãֽе¿Çâ
Antibodies in Oncology Drug Pipeline Update 2010
  Pub Time : 2010/01
  Published by : BioSeeker Group AB
¾ÏÄ¡·á¿ë Ç×ü ÆÄÀÌÇÁ¶óÀο¡ ÃÊÁ¡À» ¸ÂÃß¾úÀ¸¸ç, °³¹ß ÁøÃ´ µ¿Çâ ¹× ´Ù¾çÇÑ Ç¥Àû µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Áß±¹ÀÇ ´ÜÀÏ Å¬·Ð Ç×ü ½ÃÀå
Chinese Markets for Monoclonal Antibody
  Pub Time : 2010/01
  Published by : Asia Market Information & Development Co.
Áß±¹ÀÇ °æÁ¦ µ¿Çâ, ´ÜÀÏ Å¬·Ð Ç×ü ½ÃÀåÀÇ ÅõÀÚ È¯°æ, »ê¾÷ÀÇ ¹ßÀü, ¼ö¿ä ¹× °ø±Þ, »ê¾÷ ±¸Á¶, ½ÃÀå ä³Î ¹× ÁÖ¿ä ±â¾÷ µî¿¡ ´ëÇØ »ó¼¼È÷ Á¶»çÇϰí, 2003³â ¹× 2008³âÀÇ ½ÇÀû, 2013³â ¹× 2018³âÀÇ Àå±â ¿¹ÃøÀ» ÀüÇØµå¸³´Ï´Ù.

´ÜÀÏŬ·Ð Ç×üÀÇ Àå·¡ : ½ÃÀå ¿¹Ãø(¡­2015³â), °æÇÕ º¥Ä¡¸¶Å·, Á¦Ç° ÆÄÀÌÇÁ¶óÀÎ, °Å·¡ ºÐ¼®
The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
  Pub Time : 2009/12
  Published by : GBI Research
¼¼°è ´ÜÀÏŬ·Ð Ç×ü(MAbs) ½ÃÀåÀÇ °³¿ä, ÀáÀç ½ÃÀå, ÆÄÀÌÇÁ¶óÀÎ, M&A ÇöȲ, °æÀﱸµµ µîÀ» ºÐ¼®ÇÏ¿© ÁÖ¿ä ±â¾÷¿¡ ´ëÇÑ º¥Ä¡¸¶Å· ºÐ¼®°ú ÇÔ²² ÀüÇØµå¸³´Ï´Ù.

¸ð³ëŬ·Î³Î Ç×ü : 2009³â Ãֽе¿Çâ
Monoclonal Antibodies: 2009 update
  Pub Time : 2009/11
  Published by : Datamonitor
¸ð³ëŬ·Î³Î Ç×ü ½ÃÀåÀ» Æ÷°ýÀûÀ¸·Î ºÐ¼®Çϰí, Á¦Ç°º°, ±â¾÷º°, Ä¡·á ºÐ¾ßº°, Áö¿ªº°, ±â¼úº°·Î º» 2014³â±îÁöÀÇ ¿¹Ãø, ÇâÈÄÀÇ ¹ßÀü µ¿Çâ µîÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù.

¼¼°èÀÇ Ç×»ý¹°Áú ³»¼º°ú Ç×»ý¹°Áú ±â¼ú ½ÃÀå
Antibiotic Resistance and Antibiotic Technologies: Global Markets
  Pub Time : 2009/11
  Published by : BCC Research
¼¼°èÀÇ Ç×»ý¹°Áú ³»¼º°ú Ç×»ý¹°Áú ±â¼ú ½ÃÀå¿¡ ´ëÇØ »ó¼¼È÷ ºÐ¼®Çϰí, 2008³â ½ÃÀå µ¥ÀÌÅ͸¦ ¹ÙÅÁÀ¸·Î ÇÑ 2009³âºÎÅÍ 2014³â±îÁöÀÇ ¼ºÀå·ü, ´Ù¾çÇÑ Á¦Ç° °³¿ä, Á¤ºÎÀÇ ±ÔÁ¦¿¡ ÃÊÁ¡À» ¸ÂÃß¾î ÀüÇØµå¸³´Ï´Ù.

¸é¿ª¿ä¹ý°ú ¹é½ÅÀÇ »õ·Î¿î ÀûÀÀ
Immunotherapies and Vaccines for Nontraditional Indications
  Pub Time : 2009/10
  Published by : Insight Pharma Reports
¾ËÃ÷ÇÏÀ̸Ӻ´°ú ÀÇÁ¸Áõ, ±×¹ÛÀÇ ½Å°æ°è ÁúȯÀ» Æ÷ÇÔÇÑ ¸é¿ª¿ä¹ýÀÇ »õ·Î¿î ÀûÀÀ¿¡ ´ëÇØ Á¶»çÇϰí, °¢ Áúȯ¿¡ °üÇÑ º´Å»ý¸®ÇÐ, ¿ªÇÐ, ÇöÀçÀÇ ¾à¹°Ä¡·á µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Ç÷¾×ÇüÀÇ ºÐ·ù, ÆÇÁ¤ ¹× °¨¿°Áõ ½ºÅ©¸®´× °Ë»ç : ±âÁ¸/½ÅÈï °Ë»ç¹ýÀÇ ºÐ¼® ¹× ½Å±â¼ú¡¤Á¦Ç° °³¹ß ±â¾÷
Blood Typing, Grouping and Infectious Disease Screening Tests:Analysis of Current and Emerging Assays and Companies Developing New Technologies and Products
  Pub Time : 2009/09
  Published by : Venture Planning Group
Ç÷¾×ÇüÀÇ ºÐ·ù, ÆÇÁ¤ °Ë»ç, °¨¿°Áõ ½ºÅ©¸®´× °Ë»ç¿¡ ´ëÇØ »ó¼¼È÷ ºÐ¼®ÇßÀ¸¸ç, °¢°¢ÀÇ ºÐ¼®±â¼úÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ð³ëÅ©·Î³¯ Ç×ü Ä¡·á : 2009¡­2024³â
Monoclonal Antibody Therapeutics 2009-2024
  Pub Time : 2009/08
  Published by : Visiongain
¸ð³ëÅ©·Î³¯ Ç×ü ½ÃÀåÀÇ ¸ÅÃâ ¿¹Ãø°ú °³¹ß µ¿Çâ, Áß±¹ ¹× Àεµ µîÀÇ ½ÅÈï ½ÃÀå µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.

´ÜÀÏŬ·ÐÇ×ü : ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× °æÇÕ °³¿ä
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment Overview
  Pub Time : 2009/08
  Published by : Insight Pharma Reports
ÇâÈÄ À¯¸ÁÇÑ Á¦Ç°ÀÇ °³¿ä ¹× ÀûÀÀ, ´ÜÀÏŬ·ÐÇ×ü Ä¡·áÀÇ ºñ¿ë ¹× ¹Ì±¹¿¡¼­ÀÇ ÀÇ·á ¹®Á¦, 250°³ Èĺ¸ÀÇ ÀÓ»ó½ÇÇè ÆÄÀÌÇÁ¶óÀÎ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Ä¡·á¿ë ¸ð³ëŬ·Î³Î Ç×ü ½ÃÀå
Therapeutic Monoclonal Antibodies Markets
  Pub Time : 2009/06
  Published by : Trimark Publications
½ÅÈï Ä¡·á¿ë ¸ð³ëŬ·Î³Î Ç×ü ½ÃÀå¿¡ ´ëÇØ ºÐ¼®ÇÏ°í ¹Ì±¹ ¹× ¼¼°èÀÇ ¸ÅÃâ µ¿Çâ, ½ÃÀå ºÎ¹®º° ±Ô¸ð¿Í ¼ºÀå Àü¸Á, ±â¼ú °³¹ß µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Ç×ü ½ÃÀå : °ø±Þ¾÷ü¿¡°Ô ÀÖ¾î ¼º°øÀÇ ¿­¼è(Á¦3ÆÇ)
The Market for Antibodies: Keys to Success for Commercial Suppliers, Vol. III
  Pub Time : 2009/05
  Published by : BioInformatics, LLC
°úÇÐÀÚ°¡ ¿¬±¸¿¡ »ç¿ëÇÏ´Â Ç×üÀÇ Á¾·ù¿¡ ´ëÇØ ºÐ¼®ÇÏ°í °ú°Å 12°³¿ù°£ °¡Àå ¼±È£µÈ °ø±Þ¾÷ü¿Í ÇâÈÄ ¿¹Ãø, Ç×ü ½ÃÀå ÀüüÀÇ ½ÇÀû°ú °æÇÕ µ¿Çâ, ½ÃÀå Á¡À¯À² µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀåÀÇ °Å·¡¿Í ¾÷°è Àü¸Á
Dealmaking and Industry Outlook: Antivirals
  Pub Time : 2009/05
  Published by : Decision Resources, Inc.
Ç×¹ÙÀÌ·¯½º ½ÃÀåÀÇ ±Ô¸ð ¹× º£½ºÆ® ¼¿·¯ ºê·£µå, ÁÖ¿ä ±â¾÷ÀÇ °³¿ä¿Í ÇÔ²² ±â¼ú°³¿ä, ÀÛ¿ë ±â¼­, ¶óÀÌÇÁ »çÀÌŬ °ü¸® µîÀÇ Àü·«, °¢»çÀÇ °Å·¡ °³¿ä¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¾Ï Ä¡·áÀÇ ¸ð³ëŬ·Î³Î Ç×ü : 2009-2024³â
Monoclonal Antibodies in Cancer Therapy 2009-2024
  Pub Time : 2009/05
  Published by : Visiongain
¾Ï Ä¡·áÀÇ ¸ð³ëŬ·Î³Î Ç×ü ½ÃÀå¿¡ ´ëÇÑ 2009-2024³â ¸ÅÃâ ¿¹Ãø°ú ¾àÁ¦ °³¹ß µ¿Çâ, ÁÖ¿ä 10 Ç׸ñÀÇ ¸ÅÃâ°ú ½ÃÀåÁ¡À¯À², Áß±¹ ¹× Àεµ µîÀÇ ½ÅÈï±¹À» Æ÷ÇÔÇÑ ±¹°¡º° µ¿Çâ µîÀ» ÇÔ²² ÀüÇØµå¸³´Ï´Ù.

¾Ï Ä¡·á¿ë Ç×ü¿Í ¹é½Å : °Å·¡ µ¿Çâ ¹× ¾÷°è Àü¸Á
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
  Pub Time : 2009/04
  Published by : Decision Resources, Inc.
¾Ï Ä¡·á¸¦ À§ÇÑ Ç×ü ¹× ¹é½Å ½ÃÀå¿¡ ´ëÇØ ºÐ¼®Çϰí, ÇöÀçÀÇ ½ÃÀå µ¿Çâ, ¾÷°èÀÇ °úÁ¦, ÃÖ±Ù¿¡ ÇàÇØÁø µ¿ ºÐ¾ßÀÇ ±â¾÷ ¸Å¼ö, Á¦ÈÞ µ¿Çâ, ÇâÈÄ Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Rituxan »ç·Ê¿¬±¸ : Áö¹èÀûÀÎ Ä¡·á ÆÐ·¯´ÙÀÓÀ» º¯È­½Ã۱â À§ÇÑ Ãâ½Ã Àü Ä¿¹Â´ÏÄÉÀ̼Ç
Rituxan Case Study: Pre-Launch Communications to Change the Dominant Treatment Paradigm
  Pub Time : 2009/02
  Published by : Best Practices, LLC
Genentech°¡ ·ù¸¶Æ¼½º °üÀý¿° Ä¡·á¾àÀ¸·Î¼­ ÆÇ¸ÅÇÏ´Â Rituxan¿¡ ´ëÇØ ºÐ¼®Çϰí, ½ÃÀåÂü°¡ÀÇ ¹è°æ°ú Ãâ½Ã Àü ÁÖ¿ä ¿ÀÇǴϾ𠸮´õ(KOL)¿ÍÀÇ Ä¿¹Â´ÏÄÉÀ̼Ç, Ãâ½Ã Àü ¹× Ãâ½Ã ÈÄÀÇ µ¿Çâ, ±³ÈÆ µîÀ» ÀüÇØµå¸³´Ï´Ù.

¾Ï ¹× °¨¿°ÁúȯÀ» À§ÇÑ ¸é¿ª¿ä¹ý°ú ¹é½Å
Immunotherapies and Vaccines for Cancer and Infectious Diseases Report
  Pub Time : 2008/10
  Published by : Insight Pharma Reports
°¨¿°Áúȯ ¹× ¾Ï¿¡ ´ëÇÑ ¸é¿ª¿ä¹ý°ú ¹é½Å ºÐ¾ßÀÇ µ¿Çâ¿¡ ÃÊÁ¡À» ¸ÂÃß¾î, ¿¬±¸ÀÚ ¹× ±â¾÷ÀÌ Á÷¸éÇÑ °úÁ¦¿Í À庮, ÇâÈÄÀÇ Àü¸Á, Àü¹®°¡ÀÇ °ßÇØ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

À¯·´ÀÇ ¸é¿ª ÃøÁ¤ ½ÃÀå : Àü·« ºÐ¼®
Strategic Analysis of the European Immunoassay Market
  Pub Time : 2008/10
  Published by : Frost & Sullivan
À¯·´ ÁÖ¿ä 7°³±¹ÀÇ ¿¬±¸ ¹× Æ÷ÀÎÆ® ¿Àºê ÄɾîÀÇ ¸é¿ª ÃøÁ¤ ½ÃÀå¿¡ ´ëÇØ ºÐ¼®ÇÏ°í µ¿Çâ°ú °æÇÕ Àü·«, °úÁ¦ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¼¼°èÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå ºÐ¼® ¹× ¿¹Ãø : 2008¡­2013³â
Global Antivirals Market Analysis & Forecasts 2008-2023
  Pub Time : 2008/09
  Published by : Visiongain
Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå¿¡ ´ëÇÑ ºÐ¼® ¹× ±âȸ, ÁÖ¿ä ½ÃÀåÂü°¡±â¾÷, 2008¡­2023³âÀÇ ½ÃÀå ¿¹Ãø, Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå¿¡ ´ëÇÑ À§Çù µî¿¡ ´ëÇØ Àü¹®°¡ÀÇ °ßÇØ¿Í ÇÔ²² ÀüÇØµå¸³´Ï´Ù.

À¯·´ÀÇ Ä¡·á¿ë ´ÜÀÏŬ·Ð Ç×ü ½ÃÀå
European Therapeutic Monoclonal Antibody Markets
  Pub Time : 2008/08
  Published by : Frost & Sullivan
À¯·´ÀÇ Ä¡·á¿ë ´ÜÀÏŬ·Ð Ç×ü ½ÃÀåÀÇ ½ÃÀå ÃËÁø ¿äÀÎ, ¾ïÁ¦ ¿äÀÎ, »ê¾÷ °úÁ¦, ¼öÀÍ ¿¹Ãø, °ø±Þ¸Á ºÐ¼®, Ãßõ Àü·« µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Ä¡·á¿ë ´ÜÀÏŬ·Ð Ç×ü : 2008¡­2023³â
Therapeutic Monoclonal Antibodies Report 2008-2023
  Pub Time : 2008/07
  Published by : Visiongain
´ÜÀÏŬ·Ð Ç×ü¿¡ °üÇÑ ±â¼ú µ¿Çâ, Ä¡·á ºÐ¾ß, 2008³âºÎÅÍ 2023³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø, ½ÃÀå Âü°¡ µ¿Çâ ¹× ÇâÈÄ ½Å¾à °³¹ß µ¿Çâ µîÀ» ÀüÇØµå¸³´Ï´Ù.

¹Ì±¹ ¹× ¼¼°èÀÇ ¸ð³ëŬ·Î³Î Ç×ü ¾àÁ¦
U.S. and Worldwide Monoclonal Antibody Medicine
  Pub Time : 2008/07
  Published by : Fuji-Keizai U.S.A., Inc.
ÇöÀç Ãâ½ÃµÈ ¶Ç´Â °ð Ãâ½Ã ¿¹Á¤ÀÎ Ç×ü ÀǾàǰÀ» ¼ÒÀ¯ÇÑ ¹ÙÀÌ¿ÀÆÄ¸Ó ±â¾÷ÀÇ È°µ¿À» ºÐ¼®Çϰí, Á¦¾àȸ»çÀÇ Ç×ü ¿¬±¸°³¹ß µ¿Çâ, Á¦ÈÞ, ÅõÀÚ µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Ç×»ý¹°ÁúÀÇ R&D : ¹ÌÃæÁ· ¼ö¿äÀÇ ÃæÁ·°ú »ó¾÷È­ÀÇ ¾ç¸³
Antibiotic R&D: Resolving the Paradox between Unmet Medical Need and Commercial Incentive
  Pub Time : 2008/07
  Published by : Insight Pharma Reports
Ç×»ý¹°ÁúÀÇ R&D, »ó¾÷È­ÀÇ °úÁ¦, ½ÃÀå±âȸ¸¦ Á¶»ç ºÐ¼®ÇÏ°í ½ÃÀ强Àå¿¡ ´ëÇÑ °¢Á¾ ¿µÇâ¿äÀÎ, ¾àÁ¦³»¼º±ÕÀÇ °úÁ¦¿Í 󸮼ö´Ü, Ç×»ý¹°Áú R&DÀÇ °æÁ¦ ¹× ±ÔÁ¦, ÆÄÀÌÇÁ¶óÀÎ Á¦Ç° µ¿Çâ, ºí·Ï¹ö½ºÅÍ ¸ðµ¨À» ´ëüÇÏ´Â »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨ÀÇ °íÂû, Àü¹®°¡ÀÇ ÀÎÅÍºä µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Áß±¹ÀÇ ¼¼ÆÈ·Î½ºÆ÷¸° ½ÃÀå
Chinese Markets for Cephalosporins
  Pub Time : 2008/06
  Published by : Asia Market Information & Development Co.
Áß±¹ÀÇ °æÁ¦ µ¿Çâ, ÅõÀÚ È¯°æ, »ê¾÷ÀÇ ¹ßÀü, ¼ö¿ä¿Í °ø±Þ, »ê¾÷ ±¸Á¶, ½ÃÀå °æ·Î ¹× ÁÖ¿ä ±â¾÷ µî¿¡ ´ëÇØ »ó¼¼È÷ Á¶»ç ºÐ¼®Çϰí 1997, 2002, 2007³âÀÇ ½ÇÀû ¹× 2012³â°ú 2017³âÀÇ Àå±â ¿¹ÃøÀ» Á¦½ÃÇØµå¸³´Ï´Ù.

¾Ï Ç×ü : ¼º°øÀ» À§ÇÑ °æÇÕ Æ÷Áö¼Å´×
Cancer Antibodies: Competitive Positioning for Success
  Pub Time : 2008/06
  Published by : BioSeeker Group AB
ÇöÀç ¹× ÇâÈÄÀÇ ¾Ï Ç×ü ½ÃÀåÀ» ºÐ¼®Çϰí ÀǾàǰ ¾÷°è ³»¿¡¼­ÀÇ °æÇÕ µ¿Çâ, °³¹ßÁßÀÎ ¾àÁ¦ µ¿Çâ, ¾Ï Ç×ü ¾àÁ¦Ç¥ÀûÀÇ ÇÁ·ÎÆÄÀϸµ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¹Ì±¹ÀÇ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö : Ä¡·á¿ë ¸ð³ëŬ·Î³Î Ç×ü ½ÃÀå
U.S. Biotechnology - Therapeutic Monoclonal Antibodies Market
  Pub Time : 2008/05
  Published by : Frost & Sullivan
2004³âºÎÅÍ 2014³â±îÁö ¹Ì±¹ÀÇ Ä¡·á¿ë ¸ð³ëŬ·Î³Î Ç×ü ½ÃÀåÀ» ºÐ¼®Çϰí ÁúȯÀÇ °³¿ä, ±â¼ú µ¿Çâ, ½ÃÀå ÀüüÀÇ ¼öÀÍ ¿¹Ãø, ºÎ¹®º° ¼öÀÍ ¿¹Ãø, ½ÃÀå Á¡À¯À² ºÐ¼®, ½ÃÀåÀÇ °úÁ¦ µîÀ» °ËÁõÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¼¼°èÀÇ Ç×»ý¹°Áú ½ÃÀå
Antibiotics
  Pub Time : 2008/05
  Published by : Global Industry Analysts, Inc.
¼¼°èÀÇ Æä´Ï½Ç¸°°è, ¼¼ÆÈ·Î½ºÆ÷¸°°è, ¸ÅÅ©·Î¶óÀ̵å(Macrolides)°è, Äû³î·Ð(Quinolones)°è Ç×»ý¹°Áú ½ÃÀåÀÇ ºÏ¹Ì, ij³ª´Ù, ÀϺ», À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç Áö¿ª, ±âŸ Áö¿ªº° ºÐ¼®°ú ÇöÀç±îÁöÀÇ ½ÇÀû ¹× Àå·¡ ¿¹Ãø, ´ë±Ô¸ð, Æ´»õ ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏ µîÀ» Á¦°øÇÕ´Ï´Ù.

¾ÏÄ¡·á¿¡¼­ Ç×ü ±â¼úÀÇ Àü°³
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
  Pub Time : 2008/04
  Published by : BioSeeker Group AB
¾ÏÄ¡·áÀÇ ´ÜÀÏ Å¬·Ð Ç×ü ½ÃÀå µ¿Çâ°ú ÁÖ¿ä Ç×ü ±â¼ú, Â÷¼¼´ë Ä¡·á¿ë Ç×üÀÇ °æÀï, Ç×üÀÇ ¹ß°ß, µô¸®¹ö¸® ¹× °³·® ºÎ¹®ÀÇ °æÇÕ µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

°¨¿°¼ºÁúȯ Ä¡·áÀÇ »ý¹°Á¦Á¦ ½ÃÀå µ¿Çâ
Stakeholder Opinions: Biologics in Infectious Diseases - Well defined target populations are key to commercial success
  Pub Time : 2008/03
  Published by : Datamonitor
°¨¿°¼ºÁúȯ Ä¡·áÀÇ »ý¹°Á¦Á¦¿¡ °üÇÑ ÁÖ¿ä °³¹ß¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí À¯¸ÁÇÑ Å¸°Ù, °³¹ß»óÀÇ ¹®Á¦Á¡, Ç×±Õ, Ç×¹ÙÀÌ·¯½º, Ç×Áø±ÕÀÇ °¢ ÆÄÀÌÇÁ¶óÀÎ °èȹ °³¿ä µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

»ý¹°¾àÁ¦ °³¹ß µ¿Çâ : ÇâÈÄ À¯¸ÁÇÑ ¸ð³ëÅ©·Î³¯ Ç×ü
Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies?
  Pub Time : 2008/03
  Published by : Decision Resources, Inc.
»ý¹°¾àÁ¦ ½ÃÀåÀÇ °³¿ä ¹× 10°¡Áö ¿©·¯ ¾àÁ¦ Ŭ·¡½º¿¡¼­ÀÇ ¸ð³ëÅ©·Î³¯ Ç×ü °³¹ß µ¿Çâ, ¸ð³ëÅ©·Î³¯ Ç×ü ½ÃÀå µ¿Ç⠵ ´ëÇØ Àü¹®°¡ÀÇ ÀǰßÀ» ¼ö·ÅÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¾Ï ¼¼Æ÷Ä¡·á¹ý ½ÃÀå
Cancer Cell Therapy Markets
  Pub Time : 2008/03
  Published by : Trimark Publications
¾ÏÀÇ ¼¼Æ÷Ä¡·á¹ý »óȲ°ú °³¹ßÁßÀÎ ¹é½Å, °æÇÕÇϰí ÀÖ´Â ±âŸ Ç×üġ·á¹ý µ¿Çâ, ±ÔÁ¦ µ¿Çâ ¹× Âü°¡±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» ÀüÇØµå¸³´Ï´Ù.

À¯·´ÀÇ ¸é¿ªÈ­ÇÐ ºÐ¼®ÀåÄ¡ ½ÃÀå
European Immunochemistry Analysers Markets
  Pub Time : 2008/01
  Published by : Frost & Sullivan
À¯·´ÀÇ ¸é¿ªÈ­ÇÐ ºÐ¼®ÀåÄ¡ ½ÃÀåÀ» Á¶»çÇÏ°í ±× °úÁ¦, ÇâÈÄ ¿¹Ãø, Àü·«Àû Á¦¾ð µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¼¼°èÀÇ ¸é¿ªÈ­ÇÐ ½ÃÀå
Global Immunochemicals Markets
  Pub Time : 2008/01
  Published by : Frost & Sullivan
¼¼°è ¸é¿ªÈ­ÇÐ ½ÃÀåÀÇ °³¿ä, °úÁ¦, ¹ßÀü¿äÀÎ ¹× ÀúÇØ¿äÀÎ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¸ð³ëŬ·Î³Î ¿ä¹ý ¹× ÄÄÆÐ´Ï¾ð Áø´Ü Á¦Ç°
Monoclonal Therapeutics and Companion Diagnostic Products
  Pub Time : 2008/01
  Published by : BCC Research
¸ð³ëŬ·Î³Î Ç×ü ±â¼úÀÇ °³¿ä, Ä¡·á ¹× Áø´Ü¿ë ¸ð³ëŬ·Î³Î Ç×üÀÇ Àû¿ë, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Ç×»ý¹°Áú°ú ¾àÁ¦³»¼º : 2008³â
Antibiotics and Drug Resistance 2008
  Pub Time : 2008/01
  Published by : BioPharm Reports (Technology and Markets Ltd)
Ç×»ý¹°ÁúÀÇ ³»¼º ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ½Å¾à°³¹ß°ú Àü·«¿¡ °üÇØ ºÐ¼®Çϰí, ÇöÀçÀÇ Á¶»ç Ȱµ¿, °ú°Å 6³â°£ÀÇ Æ¯Çã µ¿Çâ, Ç×»ý¹°ÁúÀÇ °³¹ß µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Â÷¼¼´ë »ý¹°ÇÐ : ¸ð³ëŬ·Î³ÎÇ×üÀÇ °³·®
Next-Generation Biologics: Improving on Monoclonal Antibodies
  Pub Time : 2007/12
  Published by : Decision Resources, Inc.
¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ °³¿ä, ¸ð³ëŬ·Î³ÎÇ×ü ¾÷°èÀÇ °³¿ä, ´ëü ¸ð³ëŬ·Î³ÎÇ×üÀÇ Á¦Á¶ µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Ç×ü¾àÁ¦Ç¥Àû ¹× ¹éÇ÷º´¡¤¸²ÇÁÁ¾
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
  Pub Time : 2007/12
  Published by : BioSeeker Group AB
Ç×ü¾àÁ¦Ç¥ÀûÀÇ ÇöȲ ¹× °æÇÕ µ¿Çâ, ¹éÇ÷º´ ¹× ¸²ÇÁÁ¾ÀÇ ÇöÀç Ä¡·á Àü·« ¹× Ä¡·á¾à °³¹ß µ¿Çâ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Ç×üÀǾàÇ¥Àû°ú À¯¹æ¾Ï, Àü¸³¼±¾Ï
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
  Pub Time : 2007/11
  Published by : BioSeeker Group AB
Ç×üÀǾàÇ¥ÀûÀÇ °³¿ä¿Í À¯¹æ¾Ï, Àü¸³¼±¾ÏÀÇ ÇöÀç¿Í Àå·¡ ¹× Àå·¡ÀÇ Ä¡·áÀü·«, °³¹ßÁßÀÇ ¾àÁ¦ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¾ÏÄ¡·á¸¦ À§ÇÑ ¸é¿ªÁ¶Á¤Á¦
Building on Early Successes of Immunomodulators in the Fight Against Cancer
  Pub Time : 2007/09
  Published by : Decision Resources, Inc.
ÇöÀç ½ÃÀå¿¡ ³ª¿ÍÀÖ´Â ¾ÏÄ¡·á¸¦ À§ÇÑ ¸é¿ª ¾àÁ¦ÀÇ °³¿ä, Å»¸®µµ¸¶À̵å, ÅçÀ¯»ç ¼ö¿ëü, »ý¹°¾àÁ¦ÀÇ °³¿ä ¹× ÇâÈÄÀÇ ½ÃÀå Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

´ÜÀÏŬ·ÐÇ×ü ½ÃÀå µ¿Çâ (Part II)
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
  Pub Time : 2007/09
  Published by : Datamonitor
2012³â±îÁö °¢ ±â¾÷º° ´ÜÀÏŬ·ÐÇ×ü ½ÃÀåÀÇ Àü·« °³¿ä, ÁÖ¿ä ±â¾÷ÀÇ Á¦³×¸¯ ÀǾàǰ°úÀÇ °æÇÕ µ¿Çâ, ºñÁî´Ï½º ¸ðµ¨, Á¦ÈÞ ³×Æ®¿öÅ© µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

Ç×»ý¹°ÁúÀÇ ¿ø·á¿Í ÃÖÁ¾ÀǾàǰ : ·¯½Ã¾ÆÀÇ ½ÃÀåÁ¶»ç
Substances and finished pharmaceutical products of antibiotics: market research in Russia
  Pub Time : 2007/08
  Published by : INFOMINE Research Group
Ç×»ý¹°ÁúÀÇ ¿ø·á¿Í Á¦Á¶¹æ¹ý, ·¯½Ã¾ÆÀÇ ½ÃÀ嵿Çâ, Á¦Á¶¾÷ü ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¾ÏÄ¡·áÀÇ Ç×üÀǾà Ç¥Àû : ¸á¶ó³ë¸¶(Èæ»öÁ¾)¿Í ºñ¼Ò¼¼Æ÷Æó¾Ï
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
  Pub Time : 2007/07
  Published by : BioSeeker Group AB
¾ÏÄ¡·á¸¦ À§ÇÑ ¿¬±¸°³¹ß, Ç×üÀǾà Ç¥Àû¿¡ °üÇØ ºÐ¼®Çϰí, µ¿½ÃÀåÀÇ °æÇÕ µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¾Ï Ä¡·á¿¡¼­ Ç×ü ¾àǰÀÇ Ç¥Àû
Antibody Drug Target Atlas in Oncology
  Pub Time : 2007/06
  Published by : BioSeeker Group AB
´Ù¾çÇÑ ºÐÀÚ±â´ÉÀÇ °³¿ä ¹× ½Ã±×³Î Àü´Þ°æ·Î, »ç¶÷ ¼¼Æ÷ ¹× ¾Ï ¼¼Æ÷¿¡¼­ÀÇ Ç¥Àû ¹ßÇö ÇÁ·ÎÆÄÀÏ, Ç×ü Á¦¾àȸ»ç °³¿ä µîÀ» ÀüÇØµå¸³´Ï´Ù.

¸ð³ëÅ©·Î³Î Ç×ü ½ÃÀ嵿Ç⣺Part I
Monoclonal Antibodies Report Part I
  Pub Time : 2007/06
  Published by : Datamonitor
2012³â±îÁö ¸ð³ëÅ©·Î³Î Ç×ü ½ÃÀåÀÇ ÀçÁ¤Àû Àü·«ºÐ¼®, 2012³â±îÁöÀÇ Àü¼¼°è ¸ÅÃâ ¿¹Ãø, Á¦Ç°º°/±â¾÷º°/Ä¡·áºÐ¾ßº° ½ÃÀ嵿Çâ, ±â¼ú°³¹ßµ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¼¼°èÀÇ ¸ð³ëŬ·Î³Î Ç×ü, ¹é½Å ¹× ±âŸ ¸é¿ªÇÐÀû ¾ÏÄ¡·á µ¿Çâ
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments: World Market
  Pub Time : 2007/05
  Published by : Kalorama Information
¸ð³ëŬ·Î³Î Ç×ü, ¹é½Å ¹× ±âŸ »ý¹°¿ä¹ýÀÇ °³¿ä, ½ÃÀå Á¡À¯À², ±â¾÷ ÇÁ·ÎÆÄÀÏ, ¹Ì±¹, À¯·´, ÀϺ» ¹× ±âŸ °¢±¹ÀÇ ¼öÀÍ µ¥ÀÌÅÍ, 2011³â±îÁöÀÇ ¿¹Ãø, ½ÅÁ¦Ç° ÆÄÀÌÇÁ¶óÀÎ °³¿ä µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¼¼°èÀÇ Ç×¹ÙÀÌ·¯½ºÁ¦ ½ÃÀå : R&D ÆÄÀÌÇÁ¶óÀΤý½ÃÀåºÐ¼®¤ý°æÇÕȯ°æ
The Global Antivirals Market - R&D Pipelines, Market Analysis and Competitive Landscape
  Pub Time : 2007/05
  Published by : Arrowhead Publishers
CMV, HBV, HCV, HSVµîÀÇ Ä¡·á¿¡ ÀÌ¿ëµÇ´Â Ç×¹ÙÀÌ·¯½ºÁ¦ÀÇ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ°í ½ÃÀ强Àå ÃËÁøÀÎÀÚ, ÀúÇØÀÎÀÚ, °³¹ß µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ÇÁ·ÎÆÄÀÏ ¹× µ¿Çâ, ÁÖ¿ä ¾àÁ¦ Á¾·ùÀÇ °³¿ä, ÁÖ¿ä ºê·£µå & ½Åºê·£µåÀÇ ¸Å»ó ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

¸ð³ëŬ·Î³ÎÇ×ü Ä¡·á¾àÀÇ °³¹ß µ¿Çâ
Monoclonal Antibodies: what the future holds
  Pub Time : 2007/04
  Published by : Espicom Business Intelligence
°³¹ß ´Ü°è¥± ¹× ¥²¿¡ ÀÖ´Â °¢Á¾ ¸ð³ëŬ·Î³ÎÇ×ü Ä¡·á¾àÀ» Áúº´(¾Ï¤ý·ù¸ÓƼÁò)º°·Î Á¶»çºÐ¼®Çϰí, »ó¾÷ÀûÀÎ ¼º°øÀ» °ÅµÐ ±â¾÷ÀÇ ÄÉÀ̽º ½ºÅ͵ð ¹× ÇâÈÄÀÇ ½ÃÀå ¼ºÀå ÀÎÀÚ, ±â¾÷ÀÇ °æÇÕ ºÐ¼® µîÀ» Á¦°øÇÕ´Ï´Ù.

  Page:   1  2   


| Home | Contact | E-mailing | About GII | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§| Site Map |
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼Ç
Tel:02-2025-2992, Fax:02-2025-2993, E-mail :
(C) Copyright 2009, Global Information, Inc. All rights reserved.